Doripenem is a carbapenem antibiotic with broad-spectrum coverage of gram-positive and gram-negative bacteria, including Pseudomonas aeruginosa, and is considered to be as effective as meropenem. The in vivo activity of doripenem was thus compared with that of meropenem in a chronic lower respiratory P. aeruginosa infection mouse model. The number of viable bacteria in the lungs after treatment with doripenem, meropenem, and saline mice was 2.01 ± 0.69, 2.03 ± 0.48 and 3.90 ± 1.40 log 10 CFU/lung, respectively. The number of viable bacteria in the lungs of mice treated with doripenem and meropenem was significantly lower than that in lungs of controls.
Introduction
Pseudomonas aeruginosa is often involved in chronic lower respiratory tract infectious conditions, such as cystic fibrosis, diffuse panbronchiolitis, chronic obstructive pulmonary disease (COPD) and ventilator-associated pneumonia. After P. aeruginosa colonizes the lower respiratory tract, it is difficult to treat. Chronic respiratory infection causes unnecessary inflammation and lung tissue damage in humans, leading to decreased lung function. Subsequently, P. aeruginosa may cause acute exacerbation of chronic respiratory infection, and this constitutes the main cause of mortality among patients affected by this condition [1] . Such patients require treatment with antibiotics at every acute exacerbation event.
Doripenem (DRPM) is a carbapenem antibiotic with broad spectrum activity against gram-positive and gram-negative bacteria, including P. aeruginosa, and it also has potent in vitro activity against many multidrug-resistant hospital pathogens [1] [2] [3] . Against some pathogens, the activity of DRPM is slightly higher than that of meropenem(MEPM) and imipenem(IPM) [1, 2, [4] [5] [6] , and the chemical structure of DRPM is very similar to that of MEPM. DRPM and MEPM, unlike IPM, both have a 1-beta-methyl side chain that provides stability against human renal dehydropeptidase-I (DHP-I). In DRPM, however, the dimethylcarbamoyl side chain of MEPM is replaced with a sulfamoylaminomethyl group. The MIC 90 s of DRPM, MEPM and IPM against the Araki et al., Page 4 of 14 clinical isolates of P. aeruginosa from hospitals located in the Americas and Europe are 0.5, 1 and 2 g/ml, respectively [1] .
In this study, we investigated the efficacy of DRPM, as compared to MEPM, in a chronic lower respiratory tract P. aeruginosa infection model. 
Materials and methods

Antimicrobial agents
Laboratory animals
Male, ddY, specific pathogen-free mice (age, 5 -6 weeks; body weight, 30 -35 g) were purchased from Shizuoka Agricultural Cooperative Association Laboratory Animals (Shizuoka, Japan). All animals were housed in a pathogen-free environment and received sterile food and water in the Laboratory Animal Center for Biomedical Science at Nagasaki University. The experimental Araki et al., Page 5 of 14 protocol was approved by the Ethics Review Committee for Animal Experimentation at our institution.
2.3. Bacterial strains P. aeruginosa S10 strain, which was isolated from sputum of patiants with chronic respiratory infection at Nagasaki University Hospital, was used in this study. S10 is a mucoid strain, and we have reported that S10 is suitable strain to make a murine model of chronic respiratory infection in the previous study [7] , [8] . Bacteria were stored at -80°C in Microbank TM (Pro-Lab Diagnostics Inc., Toronto, Canada) until use.
Antibiotic susceptibility testing
The MICs of the agents were determined by the broth dilution method with Mueller-Hinton broth (Becton Dickinson and Company, Franklin Lakes, NJ). Microtiter plates containing 5.0  10 4 CFU/well were incubated with agents at 37°C for 24 h and the lowest concentration of agent that prevented visible growth was considered to be the MIC.
Experimental model of chronic respiratory infection
Araki et al., Page 6 of 14 Disposable sterile plastic cut-down intravenous catheters with a 3 Fr. (1 mm) outer diameter (Atom Co., Tokyo, Japan) were used for intubation. The tubes were 5.0 mm in length, with a few slits made at the proximal end to prevent blockage by oral secretions. To prepare inoculum, P.
aeruginosa was cultured on a Muller-Hinton II agar plate for 24 h, and bacteria were then suspended in saline, harvested by centrifugation (3,000  g, 4°C, 10 min), resuspended in sterile saline and adjusted to 2  10 9 CFU/ml, as estimated by turbidimetry. The intubation tube was then immersed in the bacterial saline suspension for 3 days at 37°C. The bacterial count on these tubes 3 days after incubation and just prior to intubation was 6.0 ± 0.3 (log 10 CFU/ml, mean ± SD, n = 5).
The method used for inducing infection has been described in detail previously [7] , [8] .
Briefly, the intubation tube harbouring bacteria was attached to the blunted tip of the needle of an intravenous catheter (Angiocath; Beckton Dickinson, Vascular Access Sandy, UT). The needle-tube was inserted through the oral cavity, and was then advanced through the vocal cords. When the tip of the tube was in the trachea, the needle/catheter was pulled out and the outer sheath was pushed gently to place the pre-coated tube into the main bronchus.
Treatment protocol
Lower airway infection was induced in mice with P. aeruginosa, as described above. DRPM or MEPM was injected intraperitoneally into the mice twice a day (100 mg/kg) beginning at 7 days Araki et al., Page 7 of 14 after inoculation. The same dosage of cilastatin (Wako Pure Chemical Industries, Ltd., Osaka, Japan), a DHP-I inhibitor, was also injected along with both agents. In the control group, saline was injected into mice instead of DRPM or MEPM. A total of 7 -10 mice were used for each group.
Bacteriological examination
Mice were sacrificed by cervical dislocation on day 14 (12 h after final treatment). Lungs were dissected under aseptic conditions and were suspended in 1 ml of saline. Organs were homogenized with a homogenizer (AS One Co., Osaka, Japan), were quantitatively inoculated onto Muller-Hinton II agar plates using serial dilutions, and were incubated at 37°C for 18 h.
Histological examination
Mice were sacrificed by cervical dislocation on day 14 (12 h after final treatment). Lungs were fixed in 10% buffered formalin, and were stained with hematoxylin-eosin.
Statistical analysis
Bacterial data are expressed as means ± SD. Differences between groups were examined for statistical significance by unpaired U test. A p value of less than 0.05 denoted the presence of a statistically significant difference. Araki et al., Page 8 of 14
Results
In vitro susceptibility
Against P. aeruginosa S10, the MICs of DRPM and MEPM were 0.25 and 0.5 g/ml, respectively. (Fig. 1) The mean colony-forming units (CFU) ± SD of P. aeruginosa recovered from homogenized lung tissue after treatment are shown in Figure 1 . The mean number of viable bacteria in the lungs of DRPM, MEPM and control mice was 2.01 ± 0.69, 2.03 ± 0.48 and 3.90 ± 1.40 log 10 CFU/lung, respectively. The number of viable bacteria in the lungs of mice treated with DRPM or MEPM was significantly less than that in lungs of controls (p < 0.05 for each comparison). There were no significant differences in the number of viable bacteria in the lungs between the DRPM-and MEPM-treated mice (p = 0.99). (Fig. 2) The histopathological findings of lung specimens from mice sacrificed at 12 h after the final treatment are shown in Figure 2 . In the control group, microscopic examination of the lung specimens confirmed the features of chronic bronchitis. Inflammatory cells had infiltrated around the Araki et al., Page 9 of 14 bronchi and exudates had collected in the alveolar spaces. However, both the DRPM-and MEPM-treated groups showed fewer inflammatory cells and exudates than the control group. There were no significantly different findings between the DRPM-and MEPM-treated groups.
Bacteriological examination
Histopathological examination
Discussion
DRPM was developed in Japan for use as a single agent in various infectious diseases.
In Europe and the United States, DRPM has been approved for the treatment of hospital-acquired pneumonia, complicating urinary tract infections and intra-abdominal infections, by the European Medicines Evaluation Agency and the US Food and Drug Administration (US-FDA), respectively [9] , [10] . DRPM has wide-spectrum antibacterial activity against gram-positive and gram-negative bacteria, and is particularly effective against P. aeruginosa in vitro when compared with other carbapenems, such as MEPM. P. aeruginosa is now being recognized as a relevant pathogen in chronic obstructive pulmonary disease (COPD) [11] . In COPD, after a clone is established, it remains in the lung for long periods, and can develop increasing degrees of antibiotic resistance and strong diversification [11] .
Araki et al., Page 10 of 14 Carbapenems are hydrolyzed at the β-lactam ring by mammalian DHP-I [12, 13] .
Therefore, IPM requires the DHP-I inhibitor cilastatin when used for therapy in humans.
However, 1-β-methylcarbapenems such as MEPM, ertapenem and DRPM show high stability in the presence of human DHP-I [14] and do not require a DHP-I inhibitor. On the other hand, DHP-I activity against DRPM and MEPM varies greatly with experimental animal species [15] .
To minimize the effects of murine DHP-I, we treated mice with cilastatin in both the DRPM and MEPM treatment groups in this study.
In the present study, we investigated that the in vivo activities of DRPM and MEPM toward P. aeruginosa in a chronic respiratory infection mouse model. DRPM was found to reduce the number of viable bacteria and to prevent inflammation in the lungs to almost the same degree as MEPM. DRPM is as effective as MEPM in adults with complicating intra-abdominal infection, and its safety profile is not significantly different [16] . Furthermore, in patients with ventilator-associated pneumonia, 4-h intravenous infusion of DRPM was clinically efficacious and therapeutically noninferior to IPM [17] . These observations are consistent with results of our study.
We evaluated the antibacterial profile of DRPM against P. aeruginosa S10 strain in vivo, and the present results can be applied to clinical practice for chronic respiratory tract infections. 
